SLIDESHOW: The 25 Most Shorted Stocks of the Nasdaq 100
By Dividend Channel Staff, 04/15/2019
This Slide: #4 of 25 |
(4) BioMarin Pharmaceutical Inc (NASDAQ:BMRN) — 10.20 Days to Cover
As of: | Total Shares Short: | Avg. Daily Volume | Days to Cover |
---|---|---|---|
04/15/2019 | 9,254,482 | 907,635 | 10.20 |
BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy.
|
Open the Dividend Channel BMRN Page (in a new window) »
|
Buy (3.36 out of 4) 54th percentile
(ranked higher than approx. 54% of all stocks covered)
Analysts' Target Price: BMRN Forecast Based on data provided by Zacks Investment Research via Quandl.com |
|